Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
September 7, 2026

Rezvilutamide / SHR3680 for Metastatic Prostate Cancer as of August 2026

MARA Rating Company September 7, 2026

Orzeyful / Oveporexton for Narcolepsy Type 1 as of August 2026

MARA Rating Company September 7, 2026

Tryngolza / Olezarsen for Severe Hypertriglyceridemia as of August 2026

MARA Rating Company September 7, 2026

Ubeslo / Obicetrapib for Primary Hypercholesterolaemia and Mixed Dyslipidaemia as of August 2026

MARA Rating Company September 7, 2026

Mezigdomide for Adult Relapsed or Refractory Multiple Myeloma as of August 2026

MARA Rating Company September 7, 2026

OTARMENI / Lunsotogene parvec-cwha for Biallelic OTOF Variant-Associated Hearing Loss as of August 2026

MARA Rating Company September 7, 2026

LYNAVOY / Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis as of August 2026

MARA Rating Company September 7, 2026

Lerodalcibep for Hypercholesterolaemia as of August 2026

MARA Rating Company September 7, 2026

Insulin efsitora alfa for Adults With Type 2 Diabetes as of August 2026

MARA Rating Company September 7, 2026

ICOTYDE / Icotrokinra for Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents Aged Twelve Years and Older Weighing at Least Forty Kilograms as of August 2026

MARA Rating Company September 7, 2026